Small molecule · Inhibitor of fatty acid synthase (FASN) · developed by Sagimet Biosciences
Denifanstat is an orally bioavailable inhibitor of fatty acid synthase (FASN), an enzyme that drives de novo synthesis of palmitic acid. By blocking FASN it reduces palmitate needed for tumor cell growth and survival. It is studied in KRAS-mutated tumors, acne vulgaris, and steatohepatitis (MASH/NASH), among other conditions.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07863193 | Phase 3 | Acne Vulgaris | Recruiting | SGMT |
| NCT03808558 | Phase 2 | KRAS Gene Mutation | Active not recruiting | SGMT |
| NCT03938246 | Phase 2 | MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease /… | Completed | SGMT |
| NCT05835180 | Phase 1 | Non-alcoholic Steatohepatitis | Completed | SGMT |
| NCT05657834 | Phase 1 | Healthy Volunteers | Completed | SGMT |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Acne VulgarisKRAS Gene MutationCirrhosisHealthy VolunteersHepatic ImpairmentNon-alcoholic Steatohepatitis
Updated Nov 1, 2026. Something wrong or missing? Report it on the SGMT page.
See SGMT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
SGMT catalysts and pipeline →